Trodelvy

News

AstraZeneca and Daiichi Sankyo logos next to Datroway box

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.

News

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

News

Kelun's MSD-partnered TROP2 drug gets first okay in China

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th

Datroway filed for TNBC in EU after data delay

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Trodelvy-Keytruda pairing hits the spot in breast cancer

Kelun's MSD-partnered TROP2 drug gets first okay in China

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Lilly points to long-lasting weight loss with orforglipron

How to meet your physicians where they are online

Trodelvy

Editor's Picks